Navigation Links
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
Date:5/4/2009

- Company Also Submits sNDA for NEXIUM Capsules for Risk Reduction of Low-Dose Aspirin-Associated Peptic Ulcer -

WILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a product combining low dose aspirin with esomeprazole magnesium for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers in patients at risk.

AstraZeneca also submitted a supplemental new drug application (sNDA) for NEXIUM(R) (esomeprazole magnesium) for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers. NEXIUM already is approved for the risk reduction in the occurrence of gastric ulcers associated with continuous non-steroidal anti-inflammatory drug (NSAID) therapy in patients at risk for developing gastric ulcers.(1)

Low-dose aspirin is the mainstay in the prevention of cardio- and cerebrovascular events such as heart attack and stroke.(2A,3A) However, even at low doses, aspirin is associated with a risk of peptic ulcers and gastrointestinal symptoms.(3B,3C) These gastrointestinal side effects can lead patients to discontinue their aspirin therapy.(3D,3E) Discontinuation due to GI problems is associated with a three-fold higher risk of major CV events,(4A) which can occur within just 1-2 weeks of discontinuation.(4B) Up to 1 in 3 patients on low-dose ASA may develop upper GI symptoms.(5A,6A)

AstraZeneca conducted two studies to evaluate the safety and efficacy of NEXIUM in reducing the risk of gastric and/or duodenal ulcers in patients who take low dose aspirin (75-325 mg continuously during the study, which is defined as at least 5 days per week). One study compared NEXIUM 40 mg or 20 mg with placebo, while the oth
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
2. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
3. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
4. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
5. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
6. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Four studies highlighting late-breaking research advances in the treatment ... at the 50th Annual Meeting of the American Society of ... Results from a study examining the ability of ... the inner lining of blood vessels, in patients with sickle ...
... at ASH Annual Meeting- , , ... announced results of a randomized phase III study presented ... of Hematology. The study in adult patients with hematological ... syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma ...
Cached Medicine Technology:Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 2Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 3Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 4Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 5Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 6Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 7Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 8Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 9Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5
(Date:7/14/2014)... Carepoint has been designed specifically to facilitate ... intuitive interface for recording, sending, displaying and receiving ... reporting features. , Hall mc - an Ontario-based ... Rebecca de Witte to create this exciting new ... Carepoint provides seamless, real-time communication between the ...
(Date:7/14/2014)... COPENHAGEN Participation in activities that promote mental ... may help protect against the development of Alzheimer,s ... new research reported today at the Alzheimer,s Association ... , Research reported at AAIC 2014 also showed ... post-traumatic stress disorder (PTSD) may increase dementia ...
(Date:7/14/2014)... 2014 Spine Team Texas ... care—from diagnosis to treatment and recovery. Currently all physical ... in or training for certification in The McKenzie Method. ... completed the extensive program. , “We require certification of ... results in better outcomes for spine pain patients,” said ...
(Date:7/14/2014)... July 14, 2014 Cadeon Associates ... Turning Information into Money,” today announced that it ... global program that helps partners resell, deploy, and ... Spotfire® analytics platform. TIBCO Software Inc. is a ... including TIBCO Spotfire analytics, providing businesses the ability ...
(Date:7/13/2014)... Recently, TopDresses100.com, a popular dress company in the ... multi-colored Quinceanera dresses to its product line. According ... outfits are guaranteed to be quality made. Now, they ... , TopDresses100.com has a wide variety of elegant dresses ... are in stock and ready to ship. As an ...
Breaking Medicine News(10 mins):Health News:Home Health Care Professional and Marketing Firm Team Up to Create New Homecare Communication App 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 3Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 2Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 3Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2
... of different alcoholic beverages and drinking behaviour on the risk ... and Cohort of Swedish Men, to study the association between ... acute pancreatitis. In total, 84,601 individuals, aged 46-84 years, ... 513 developed acute pancreatitis. There was a doseresponse association ...
... Aug. 11 (HealthDay News) -- The HIV infection rate among ... of AIDS is 10 to 20 times greater than in ... Two percent of poor heterosexuals in those cities have ... Prevention researchers, analysis of National HIV Behavioral Surveillance System data. ...
... (WASHINGTON, August 11, 2011) According to a study ... of the American Society of Hematology (ASH), researchers ... drug that releases stem cells from the bone marrow into ... at risk for later development of abnormalities involving loss or ...
... THURSDAY, Aug. 11 (HealthDay News) -- Symptoms of Alzheimer,s ... 80, according to a new study that examined the ... The study included 105 Alzheimer,s patients and 125 ... 60 to 75 (young-old) and those 80 and older ...
... Mann HealthDay Reporter , WEDNESDAY, Aug. 10 (HealthDay ... people with an irregular heartbeat may give the old standby, ... an erratic heartbeat known as atrial fibrillation are at increased ... such as a blood clot. For this reason, they have ...
... release is available in French . , ROCKVILLE, ... Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a ... (TB) vaccine that involves people living with the human immunodeficiency ... sites in Senegal and South Africa with primary funding support ...
Cached Medicine News:Health News:Alcohol consumption in relation to acute pancreatitis 2Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Alzheimer's Harder to Detect in the Very Old 2Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 2Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 3Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 4Health News:New TB vaccine enters proof-of-concept trial in people living with HIV 2Health News:New TB vaccine enters proof-of-concept trial in people living with HIV 3
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Intermittent catheter - Ready-to-Use Sterile, Enclosed System...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
... The Model 700 Whole Blood/Optical Lumi-Aggregometer available ... This new Aggregometer measures platelet function on ... blood or optical density in plasma with ... method. The Model 700 Aggregometer also has ...
Medicine Products: